AZD4635 Pellet Coating Formulation for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The poor solubility of Compound 1, 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine, limits its bioavailability and requires a solid pharmaceutical formulation that provides ease of dosing while maintaining suitable pharmacokinetic properties.
Innovation Solution
A solid pharmaceutical formulation comprising microcrystalline cellulose pellets individually coated with a composition containing 6-(2-chloro-6-methylpyridin-4-yl)-5-(4-fluorophenyl)-1,2,4-triazin-3-amine, polyvinylpyrrolidone, sodium docusate, and poloxamer or PEGylated phospholipid, which enhances solubility and absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Quantity of substance
If Compound 1 is formulated as a powder for dosing in a mix-and-drink form, then solubility is improved, but device complexity and ease of operation deteriorate due to relative complexity of dosing and unpleasant patient experience
Solution Approach 1:
The formulation is segmented into multiple distinct components: microcrystalline cellulose pellets as the core structure, polymeric stabilizer for suspension, ionic surfactant for wetting, and non-ionic surfactant for solubilization. This segmentation allows each component to perform its specific function while collectively providing a ready-to-administer oral dosage form that improves solubility without requiring mixing preparation.
2Reliability
If Compound 1 is formulated with multiple surfactants and stabilizers, then bioavailability is improved, but manufacturing precision and device complexity increase
Solution Approach 1:
The formulation employs specific concentration ranges for each component to optimize bioavailability while maintaining manufacturability: polymeric stabilizer at 0.1-10% w/w, ionic surfactant at 0.01-1.00% w/w, and non-ionic surfactant at 0.1-10% w/w. These parameter specifications balance the need for enhanced solubility and absorption with practical manufacturing considerations, ensuring consistent quality without excessive complexity.
3Ease of operation
If Compound 1 is given as a solid oral dosage form, then ease of operation is improved, but solubility and bioavailability deteriorate due to poor intrinsic solubility
Solution Approach 1:
The invention creates a composite oral dosage form combining microcrystalline cellulose pellets with multiple functional excipients: polymeric stabilizer (e.g., polyvinylpyrrolidone), ionic surfactant (e.g., sodium docusate), and non-ionic surfactant (e.g., poloxamer or PEGylated phospholipid). This composite structure maintains the ease of administration of a solid dosage form while the combination of materials collectively enhances solubility through mechanisms including wetting, solubilization, and suspension stabilization.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation achieves higher peak concentrations and overall exposure levels, improving bioavailability and pharmacokinetic properties compared to nanosuspension formulations.
Implementation Method 1
an ionic surfactant; and a non-ionic surfactant
Implementation Method 2
a polymeric stabilizer
Data Source
AI summary
Solid pharmaceutical formulations including AZD4635 are described. The solid formulations can include a polymeric stabilizer (e.g., a polyvinylpyrollidone), an ionic surfactant (e.g., sodium docusate), and a non-ionic surfactant (e.g., a poloxamer).